Show simple item record

dc.contributor.authorMalla, Ivone.
dc.contributor.authorSelzer, Erika.
dc.identifier.citationArch Argent Pediatr . 2021 Aug;119(4)
dc.descriptionDisponible en:
dc.description.abstractAbstract in English, Spanish Hepatitis C virus infection in children occurs mainly through vertical transmission. The natural history at this age consists in a high rate of spontaneous clearance, asymptomatic infection, or minimal histological changes. Disease complications are commonly seen in adolescence or adulthood. The classic treatment with pegylated interferon and ribavirin presents adverse effects, prolonged duration and achieves sustained viral response (SVR) in 50 % of patients with genotype 1 infection (the most frequent). New direct-acting antiviral treatments have been available in recent years for their indication from 12 years of age with excellent tolerance and a high SVR rate. Expectant therapeutic behavior is suggested in asymptomatic patients until they can access to them. We report the case of an adolescent with chronic hepatitis C without cirrhosis who received 12 weeks treatment with ledipasvir/sofosbuvir, achieving SVR. Keywords: antivirals agents; hepatitis C virus; pediatrics. Sociedad Argentina de Pediatrí
dc.publisherArchivos Argentinos de Pediatríaes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.subjectAntivirals agentses
dc.subjectHepatitis C
dc.titleTreatment of hepatitis C virus infection with new direct-acting antivirals agents in pediatrics. Case reportes

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional